Skip to main
ANIK

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics Inc demonstrated strong financial performance, with management reporting that its Integrity product achieved sequential revenue growth and is projected to exceed 100% growth in 2025 compared to 2024. The company’s regenerative solutions segment experienced notable growth of 41% for the quarter, primarily attributed to the Integrity patch, indicating robust demand in its product line. Additionally, international revenue from osteoarthritis pain rose by 21% year-over-year, reflecting the company's successful expansion and strategic positioning in the orthopedic market.

Bears say

Anika Therapeutics reported a decline in revenue for multiple periods, with figures of $27.8 million and $28.2 million reflecting decreases of 5.9% and 8.2%, respectively, on a constant currency basis, indicating ongoing challenges in maintaining sales momentum. The company's gross margin fell to 56%, below the estimated 58%, due in part to persistent production yield issues impacting profitability. Additionally, international revenue from osteoarthritis pain therapies decreased by 10%, attributed to order timing and similar production challenges, reinforcing concerns regarding the company's operational efficiency and financial stability.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.